Journal ArticleDOI
Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets
TLDR
LncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target for the selective killing of cancer cells in patients.Abstract:
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential. Some lncRNAs such as PCA3 is now routinely used in the clinic for the diagnosis of prostate cancer. Single nucleotide polymorphisms (SNPs) in lncRNAs can also be used as a predictor of cancer risk. Although ongoing studies continue to unravel the underlying mechanism, some lncRNAs have been used as therapeutic targets for the selective killing of cancer cells in patients. Thus lncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target. Companies such as the Curna Inc., MiNA Therapeutics Ltd. and RaNA Therapeutics Inc. have been taking steps to develop lncRNA based strategies against cancer. In this review, we discuss the potential of lncRNAs as biomarkers and therapeutic targets in cancer patients.read more
Citations
More filters
Journal ArticleDOI
Biomarkers of gastric cancer: Current topics and future perspective.
Tasuku Matsuoka,Masakazu Yashiro +1 more
TL;DR: The current status and approaches in GC biomarker are summarized, which could be potentially used for early diagnosis, accurate prediction of therapeutic approaches and the future perspective based on the molecular classification and profiling is discussed.
Journal ArticleDOI
LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer
Gang Zhang,Shuwei Li,Jiafei Lu,Yuqiu Ge,Qiaoyan Wang,Gaoxiang Ma,Qinghong Zhao,Dongdong Wu,Weida Gong,Mulong Du,Haiyan Chu,Meilin Wang,Aihua Zhang,Zhengdong Zhang +13 more
TL;DR: MT1JP, a down-regulated lncRNA in GC, was associated with malignant tumor phenotypes and survival of GC, and it is suggested that MT1JP may act as a potential therapeutic target and prognosis biomarker for GC.
Journal ArticleDOI
Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.
Shruti Mishra,Sumit Singh Verma,Vipin Rai,Nikee Awasthee,Srinivas Chava,Kam M. Hui,Alan Prem Kumar,Kishore B. Challagundla,Gautam Sethi,Subash C. Gupta +9 more
TL;DR: How the modulation of lncRNAs by phytochemicals produce therapeutic effects on cancer and other chronic diseases is discussed in this review.
Journal ArticleDOI
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Nicola Amodio,Maria Angelica Stamato,Giada Juli,Eugenio Morelli,Mariateresa Fulciniti,Martina Manzoni,Martina Manzoni,Elisa Taiana,Elisa Taiana,Luca Agnelli,Luca Agnelli,Maria Eugenia Gallo Cantafio,Enrica Romeo,Lavinia Raimondi,Daniele Caracciolo,Valeria Zuccalà,Marco Rossi,Antonino Neri,Antonino Neri,Nikhil C. Munshi,Nikhil C. Munshi,Pierosandro Tagliaferri,Pierfrancesco Tassone,Pierfrancesco Tassone +23 more
TL;DR: A crucial role of MALAT1 in the regulation of the proteasome machinery is demonstrated, and proof-of-concept that its targeting is a novel powerful option for the treatment of MM is provided.
Journal ArticleDOI
Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.
Peixin Dong,Ying Xiong,Junming Yue,Sharon J.B. Hanley,Noriko Kobayashi,Yukiharu Todo,Hidemichi Watari +6 more
TL;DR: The latest insights into the expression pattern, biological roles and mechanisms underlying the function and regulation of NEAT1 in tumors are highlighted, and its clinical implication as a new diagnostic biomarker and an attractive therapeutic target for cancers is focused on.
References
More filters
Journal ArticleDOI
Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance
TL;DR: Results indicated that lncRNA AC096655.1-002 may be a potential biomarker in the diagnosis of gastric carcinoma and showed a remarkable improvement compared with the use of serum carcinoembryonic antigen.
Journal ArticleDOI
A Duplex Quantitative Polymerase Chain Reaction Assay Based on Quantification of α-Methylacyl-CoA Racemase Transcripts and Prostate Cancer Antigen 3 in Urine Sediments Improved Diagnostic Accuracy for Prostate Cancer
TL;DR: Urinary AMACR and PCA3 tests were superior to a serum prostate specific antigen test for detecting prostate cancer, and could serve as a surveillance test after repeat negative prostate biopsies.
Journal ArticleDOI
Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer.
Lijuan Li,Rui-Fen Sun,Yundan Liang,Xin-Min Pan,Xin-Min Pan,Zhao-Hui Li,Peng Bai,Xiaofeng Zeng,Dongxian Zhang,Lin Zhang,Linbo Gao +10 more
TL;DR: Findings suggest that SNPs in the lncRNA PRNCR1 may contribute to susceptibility to CRC.
Journal ArticleDOI
Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients
TL;DR: This study supports NEAT1 as a potential prognostic predictor with its high expression in cancer tissues and its association with carcinogenesis and progression in glioma.
Journal ArticleDOI
Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection
Bongyong Lee,Joseph Mazar,Muhammad Aftab,Feng Qi,John Shelley,Jian-Liang Li,Subramaniam S. Govindarajan,Felipe Valerio,Inoel Rivera,Tadzia Thurn,Tien Anh Tran,Darian Kameh,Vipul R. Patel,Ranjan J. Perera +13 more
TL;DR: Chromogenic in situ hybridization assay was developed to detect long noncoding RNAs in primary prostatic adenocarcinoma tissue samples, paving the way for clinical diagnostics.